COVID-19 Business Intelligence and Analysis for Clinical Laboratories, Pathology Groups and Hospital Administration

Reliable COVID-19 Business Intelligence and analysis for clinical laboratories, pathology groups and Laboratory Diagnostics.

FDA Releases Updated SARS-CoV-2 Antigen Testing Template

FDA maze of regulations
Share on facebook
Facebook
Share on twitter
Twitter
Share on linkedin
LinkedIn
Share on pinterest
Pinterest
Share on whatsapp
WhatsApp
Share on email
Email
Share on facebook
Share on twitter
Share on linkedin
Share on google
Share on whatsapp
Share on email

Antigen testing template updated to recommend including information about asymptomatic testing and multiplexed antigen tests

The US Food and Drug Administration (FDA) announced an update Oct. 26, 2020, to its recommendations for the SARS-CoV-2 antigen testing emergency use authorization (EUA) application template.

The updated recommendations to the antigen test EUA template include additional data and information that should be submitted to support claims for screening asymptomatic patients. With this, the FDA also addresses study data that is recommended when applying for multiplexed antigen tests.

The SARS-CoV-2 antigen test template update and recommendations come at a time when antigen-based COVID-19 testing is becoming more commonly and widely used. Asymptomatic testing has been a recent area of increased attention, and multiplexed tests have gained more interest from many as flu season approaches.

The US government has focused increasing attention and resources on making antigen testing more widely available because of this type of test’s rapid turnaround time and ease of use. “Expanding America’s testing capabilities is the result of partnership and ingenuity between the federal government, private sector and academia,” FDA Commissioner Stephen M. Hahn, MD, said when announcing the issuance a recent antigen EUA. “Antigen tests play an important role in the overall response against COVID-19, including as a point-of-care test that can potentially scale up to test millions of Americans quickly.”

The FDA’s updated COVID-19 antigen EUA template can be viewed here. As of Nov. 3, 7 antigen tests have been authorized by the FDA under EUA, compared to 223 molecular tests.

Related Resource:

COVID-19 TESTING DATA

Helping Your Lab Stay Afloat During Challenging Times

Dear Colleague,

Robert L. MichelIn these challenging times for our colleagues in clinical laboratories, pathology practices and hospital administration, The Dark Intelligence Group (TDIG) — through generous grants from our partners — is bringing you the COVID-19 STAT Intelligence Briefings.

We’ve added analysts, writers and skilled editors to the COVID-19 STAT team to uncover, analyze, and immediately report to you what’s happening with the SARS-CoV-2 pandemic, packaged with the insights you need to deliver quality testing for patient care and keep your lab’s financial ship afloat. As part of our mission, we are also bringing you real-time data from our partners around testing that you will not find anywhere else.

Please let me know how we can better improve this service to fit your needs. If you would like to offer a grant to keep our mission going with this site, please contact me at rmichel@darkreport.com.

Sincerely,

Robert L. Michel
President, Founder
The Dark Intelligence Group